2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
6
Triple Negative Breast Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Urinary Bladder Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Myeloma
1
Mucopolysaccharidosis I
1
Mesothelioma, Malignant
1
Lymphoma, T-Cell, Peripheral
1
Liposarcoma
1
Inhibition of Autophagy Synergizes Anti-tumor Effect
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Genetic Diseases, Inborn
1
Gastrointestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
pembrolizumab
92
Gemcitabine
56
Nivolumab
50
Cisplatin
39
atezolizumab
37
Carboplatin
30
avelumab
29
enfortumab vedotin
26
Docetaxel
23
Magnetic Resonance Spectroscopy
19
Mitomycin
17
Ipilimumab
17
Paclitaxel
16
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Clinical Trials, Phase II as Topic
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled